Hikma Pharmaceuticals (DIFX:HIK) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DIFX:HIK Hikma Pharmaceuticals PLC DIFX:HIK
79 GF Score
Price $10.23
GF Value $14.00
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

DIFX:HIK
79GF Score
Hikma Pharmaceuticals PLC DIFX:HIK
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hikma Pharmaceuticals (DIFX:HIK) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of $10.23 is trading 26.9% below its estimated GF Value™ of $14.00.

Key valuation signals for DIFX:HIK:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $14.00 vs. price of $10.23 (26.9% below fair value)
  • GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the DIFX:HIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
79GF Score

Get the complete analysis for DIFX:HIK

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.23
Price
$14.00
GF Value